Thyrocare Technologies Limited Just Missed Earnings - But Analysts Have Updated Their Models

Thyrocare Technologies Limited (NSE:THYROCARE) shareholders are probably feeling a little disappointed, since its shares fell 5.9% to ₹790 in the week after its latest quarterly results. It was not a great result overall. While revenues of ₹1.7b were in line with analyst predictions, earnings were less than expected, missing statutory estimates by 15% to hit ₹3.56 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

See our latest analysis for Thyrocare Technologies

Taking into account the latest results, the most recent consensus for Thyrocare Technologies from dual analysts is for revenues of ₹8.14b in 2026. If met, it would imply a huge 24% increase on its revenue over the past 12 months. Per-share earnings are expected to soar 40% to ₹23.25. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹8.06b and earnings per share (EPS) of ₹24.90 in 2026. The analysts seem to have become a little more negative on the business after the latest results, given the minor downgrade to their earnings per share numbers for next year.

It might be a surprise to learn that the consensus price target was broadly unchanged at ₹980, with the analysts clearly implying that the forecast decline in earnings is not expected to have much of an impact on valuation.

Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Thyrocare Technologies' rate of growth is expected to accelerate meaningfully, with the forecast 19% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 6.5% p.a. over the past five years. Other similar companies in the industry (with analyst coverage) are also forecast to grow their revenue at 18% per year. Thyrocare Technologies is expected to grow at about the same rate as its industry, so it's not clear that we can draw any conclusions from its growth relative to competitors.

The Bottom Line

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Thyrocare Technologies. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have analyst estimates for Thyrocare Technologies going out as far as 2027, and you can see them free on our platform here.

You should always think about risks though. Case in point, we've spotted 1 warning sign for Thyrocare Technologies you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.